Novartis Takes Aim At Watson Over Lotrel

Law360, New York (March 16, 2006, 12:00 AM EST) -- Swiss pharmaceutical company Novartis Corp. is suing generic drug maker Watson Pharmaceuticals on charges of infringement concerning Novartis’ hypertension treatment Lotrel.

The suit, filed earlier this week in the U.S. District Court of New Jersey, alleges that Novartis obtained a patent covering “synergistic combination therapy using benazepril and amlodipine for the treatment of cardiovascular disorders and compositions” in December 2000.

That patent, which is set to expire in December 2017, concerns “a pharmaceutical composition consisting essentially of a range of ratios of specified amounts of benazepril...
To view the full article, register now.

Law360 UK

UK Financial Services

Read Our Latest UK Legal News & Analysis

Financial Services Law360 UK and Insurance Law360 UK provide breaking news and in-depth analysis on U.K. and European Union regulation, enforcement, legislation, and litigation involving banks, investment firms, insurers, and more.